SCHEMBL26857161

SCHEMBL26857161

Cn1cccc1CNC(=O)c1cc(-c2ccc3nc(N)nn3c2)cs1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.42
▸ ADORA2A P29274 1/20 0.42
▸ ADORA2B P29275 1/20 0.42
▸ ADORA1 P30542 1/20 0.42
▸ PIK3CG P48736 6/20 0.38
▸ PIK3CD O00329 5/20 0.38
▸ MMP12 P39900 4/20 0.38
▸ PIK3CA P42336 4/20 0.38
▸ PIK3CB P42338 2/20 0.38
▸ TTK P33981 2/20 0.37
▸ MARK3 P27448 2/20 0.37
▸ RAB9A P51151 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26857110 0.86 PIK3CG (0.41) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26857115 0.85 KMT2A (0.43) MMP12KMT2A
SCHEMBL26857089 0.85 MAPK1 (0.39) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26857087 0.85 MARK3 (0.38) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26857023 0.84 PIK3CG (0.41) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26856882 0.84 MMP12 (0.53) ADORA2APIK3CGPIK3CDMMP12PIK3CB
SCHEMBL26857148 0.83 MARK3 (0.46) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26857109 0.83 MARK3 (0.41) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26857092 0.83 TTK (0.40) PIK3CGPIK3CDMMP12PIK3CAPIK3CB
SCHEMBL26857155 0.82 TTK (0.43) PIK3CGPIK3CDMMP12TTKRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-11-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230382904-A1 SUBSTITUTED 4-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)THIOPHENE-2-CARBOXAMIDE DERIVATIVES AND USE THEREOF SNCA, PSEN2, PARK7 ADORA3 713/4885ADORA2A 387/4885ADORA2B 725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback